# Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT06714266** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma (HNSCC)

## Interventions

- **DRUG:** Trilaciclib

## Key facts

- **NCT ID:** NCT06714266
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-15
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06714266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06714266, "Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06714266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*